Profiel
Kai Pinkernell worked as a Senior Director-Regenerative Cell Technology at Plus Therapeutics, Inc. and as the Chief Medical Officer & Senior Vice President at MediGene AG.
Prior to that, he was the Head-Global Clinical Business at Miltenyi GmbH from 2012 to 2016.
Pinkernell holds a doctorate from the University of Münster and an MBA from USC Marshall School of Business.
Eerdere bekende functies van Kai Pinkernell
| Bedrijven | Functie | Einde |
|---|---|---|
Miltenyi GmbH
 Miltenyi GmbH Financial ConglomeratesFinance Miltenyi Biotec GmbH provides biotechnology products and services. The firm products include MACS sample preparation, MACS cell separation, MACS flow cytometry, MACS cell culture and stimulation and MACS molecular; research areas include immunology, stem cell research, neuroscience, and cancer research. Its clinical applications include clinical development, CliniMACS system, MACS GMP products, CryoMACS freezing products, TheraSorb, graft engineering, immunotherapy, tissue regeneration and freezing products. The company was founded by Stefan Miltenyi in 1989 and is headquartered in Teterow, Germany. | Corporate Officer/Principal | 01-01-2016 |
| MEDIGENE AG | Chief Tech/Sci/R&D Officer | - |
| PLUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Kai Pinkernell
| University of Münster | Doctorate Degree |
| USC Marshall School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MEDIGENE AG | Health Technology |
| PLUS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Miltenyi GmbH
Miltenyi GmbH Financial ConglomeratesFinance Miltenyi Biotec GmbH provides biotechnology products and services. The firm products include MACS sample preparation, MACS cell separation, MACS flow cytometry, MACS cell culture and stimulation and MACS molecular; research areas include immunology, stem cell research, neuroscience, and cancer research. Its clinical applications include clinical development, CliniMACS system, MACS GMP products, CryoMACS freezing products, TheraSorb, graft engineering, immunotherapy, tissue regeneration and freezing products. The company was founded by Stefan Miltenyi in 1989 and is headquartered in Teterow, Germany. | Finance |
